Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genistein in Bladder Cancer
NCT00118040Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2005
- Primary completion
- Aug 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of genistein in bladder cancer, sponsored by National Cancer Institute. Primary endpoints: Epidermal Growth Factor Receptor (EGFR) Phosphorylation in Tumor Tissue up to 21 days and pEGFR in Benign Tissue up to 21 days. Started Jun 2005; status: completed.
02
Drugs
genistein
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00118040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00118040.